How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection?
- 27 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 40 (7), 1393-1397
- https://doi.org/10.1007/s10096-021-04165-x
Abstract
Pharmacological and clinical data regarding cefoxitin for the treatment of ESBL-producing Enterobacteriaceae-related infections are limited. We performed a multicentric prospective cohort study to evaluate continuous/prolonged, or intermittent infusion of cefoxitin. We assessed the plasma concentration as a function of the duration of infusion and then performed a simulation of the percentage of patients who would reach the PK/PD targets, set at 100% ƒT> MIC or 100% ƒT>4 MIC. Eighty-one patients were included. All patients were treated with 6 gr./day. MICs to cefoxitin ranged from 0.5 to 64 mg/L. Sixteen (19.7%) patients were infected with strains with cefoxitin MICs ≥ 8 mg/L. In all patients infected with strains with MICs ≤ 6 mg/L, PK/PD objectives (100% ƒT> MIC) were achieved with prolonged or continuous infusion. In contrast, when MICs were 8 mg/L only, continuous infusion was sufficient to achieve the PK/PD objectives (100% ƒT> MIC). Extended infusion of cefoxitin is necessary for the treatment of non-UTI ESBL-related infections.Keywords
This publication has 20 references indexed in Scilit:
- Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgeryEuropean Journal of Clinical Pharmacology, 2012
- Therapeutic drug monitoring of β-lactams in critically ill patients: proof of conceptInternational Journal of Antimicrobial Agents, 2010
- Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infectionsInternational Journal of Antimicrobial Agents, 2008
- Continuous infusion of beta-lactamsCurrent Opinion in Critical Care, 2007
- Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing StrategyClinical Infectious Diseases, 2007
- Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot studyJournal of Antimicrobial Chemotherapy, 2006
- Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolidInfectious Disease Clinics of North America, 2003
- Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic modelAntimicrobial Agents and Chemotherapy, 1994
- Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin inKlebsiella pneumoniae pneumonia and septicemia in leukopenic ratsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- Bioavailability and pharmacokinetics of cefoxitin sodiumJournal of Antimicrobial Chemotherapy, 1978